Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 5,000 shares of the firm’s stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $31.26, for a total value of $156,300.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Steven Shak also recently made the following trade(s):
- On Monday, January 23rd, Steven Shak sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $27.28, for a total value of $136,400.00.
Genomic Health, Inc. (NASDAQ:GHDX) opened at 31.88 on Tuesday. The stock has a 50 day moving average price of $30.27 and a 200 day moving average price of $29.78. Genomic Health, Inc. has a 52-week low of $22.90 and a 52-week high of $33.96. The stock’s market cap is $1.09 billion.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, February 14th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.05. Genomic Health had a negative return on equity of 14.13% and a negative net margin of 5.77%. The business had revenue of $82.70 million for the quarter, compared to the consensus estimate of $84.08 million. During the same quarter in the prior year, the company earned ($0.10) EPS. The business’s revenue was up 10.1% compared to the same quarter last year. Analysts expect that Genomic Health, Inc. will post $0.01 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP purchased a new position in Genomic Health during the third quarter worth about $398,237,000. Columbia Wanger Asset Management LLC increased its position in Genomic Health by 172.2% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 1,275,338 shares of the company’s stock worth $37,482,000 after buying an additional 806,782 shares during the last quarter. BlackRock Fund Advisors increased its position in Genomic Health by 5.5% in the third quarter. BlackRock Fund Advisors now owns 914,017 shares of the company’s stock worth $26,433,000 after buying an additional 47,996 shares during the last quarter. Renaissance Technologies LLC increased its position in Genomic Health by 5.3% in the fourth quarter. Renaissance Technologies LLC now owns 576,700 shares of the company’s stock worth $16,949,000 after buying an additional 29,100 shares during the last quarter. Finally, State Street Corp increased its position in Genomic Health by 6.6% in the fourth quarter. State Street Corp now owns 545,119 shares of the company’s stock worth $16,024,000 after buying an additional 33,975 shares during the last quarter. 89.50% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have commented on GHDX shares. Canaccord Genuity reissued a “buy” rating and set a $38.00 price objective on shares of Genomic Health in a research report on Tuesday, January 17th. TheStreet raised Genomic Health from a “d+” rating to a “c-” rating in a research report on Monday, February 27th. Zacks Investment Research lowered Genomic Health from a “buy” rating to a “hold” rating in a research report on Thursday, January 19th. Deutsche Bank AG reissued a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research report on Wednesday, January 18th. Finally, Cowen and Company lowered Genomic Health from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $35.00 to $34.00 in a research report on Wednesday, January 4th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $31.14.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.